The Diabetes CAG won a bid from Diabetes UK for funding for the ‘Effect of SGLT2 inhibitors’.
SGLT2 inhibitors are a new class of drug that have an insulin-independent mode of action, which are being used to treat type 2 diabetes. Their unique action promotes urinary glucose excretion with significant weight loss. Clinical trial programmes are under way to test their clinical utility in type 1 diabetes. However, there may be significant safety issues concerning the development of euglycaemic ketoacidosis. This study will investigate the physiological effect of SGLT2 inhibitors on glucose flux, lipolysis and ketone production during hyperglycaemia in people with absolute or relative insulin deficiency.